Skip to main content
OpenTrials

Clinical trial condition

JAK2 V617F

Explore clinical trials studying JAK2 V617F. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

JAK2 V617F trial results

Recruiting

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +24 more
Locations
  • CHU d'Angers Angers, France
  • CH d'Annecy Annecy, France
  • CH d'Argenteuil Argenteuil, France
  • CH d'Avignon Avignon, France
View all 42 locations
View Trial Details

Related conditions